宜明昂科生物医药（上海）股份有限公司（01541.HK）宣布，计划动用8750万港元自有资金，认购由维港投资提供的一款理财产品。此举旨在提升公司闲置资金的利用效率，寻求在风险可控的前提下获取稳健的财务回报。公司管理层表示，本次投资决策经过了审慎评估，符合公司资金管理策略，不会影响日常运营及主营业务发展。
宜明昂科生物医药（上海）股份有限公司（01541.HK）宣布，计划动用8750万港元自有资金，认购由维港投资提供的一款理财产品。此举旨在提升公司闲置资金的利用效率，寻求在风险可控的前提下获取稳健的财务回报。公司管理层表示，本次投资决策经过了审慎评估，符合公司资金管理策略，不会影响日常运营及主营业务发展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.